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ABSTRACT
Glucocerebrosidase is a lysosomal hydrolase involved in the
breakdown of glucosylceramide. Gaucher disease, a recessive
lysosomal storage disorder, is caused by mutations in the gene
GBA1. Dysfunctional glucocerebrosidase leads to accumulation of
glucosylceramide and glycosylsphingosine in various cell types and
organs. Mutations in GBA1 are also a common genetic risk factor for
Parkinson disease and related synucleinopathies. In recent years,
research on the pathophysiology of Gaucher disease, the molecular
link between Gaucher and Parkinson disease, and novel
therapeutics, have accelerated the need for relevant cell models
with GBA1 mutations. Although induced pluripotent stem cells,
primary rodent neurons, and transfected neuroblastoma cell lines
have been used to study the effect of glucocerebrosidase deficiency
on neuronal function, these models have limitations because of
challenges in culturing and propagating the cells, low yield, and the
introduction of exogenous mutant GBA1. To address some of these
difficulties, we established a high yield, easy-to-culture mouse
neuronal cell model with nearly complete glucocerebrosidase
deficiency representative of Gaucher disease. We successfully
immortalized cortical neurons from embryonic null allele gba−/−
mice and the control littermate (gba+/+) by infecting differentiated
primary cortical neurons in culture with an EF1α-SV40T lentivirus.
Immortalized gba−/− neurons lack glucocerebrosidase protein and
enzyme activity, and exhibit a dramatic increase in glucosylceramide
and glucosylsphingosine accumulation, enlarged lysosomes, and
an impaired ATP-dependent calcium-influx response; these
phenotypical characteristics were absent in gba+/+ neurons. This
null allele gba−/− mouse neuronal model provides a much-needed
tool to study the pathophysiology of Gaucher disease and to evaluate
new therapies.
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INTRODUCTION
The enzyme glucocerebrosidase (GCase), a lysosomal-resident
hydrolase encoded by the gene glucocerebrosidase (GBA1), is
involved in the breakdown of two substrates, glucosylceramide
(GlcCer) and glucosylsphingosine (GlcSph). Gaucher disease (GD,
MIM #606463), an autosomal recessive lysosomal storage disorder,
is caused by mutations in GBA1. Deficient GCase leads to
lysosomal substrate accumulation in cells of the macrophage
lineage and clinical manifestations including organomegaly,
anemia, thrombocytopenia, osteopenia and inflammation (Beutler
and Grabowski, 2001; Sidransky, 2004). GD is classified into three
types: a non-neuronopathic type 1, an acute neuronopathic type 2,
and a chronic neuronopathic type 3, with a broad continuum of
clinical manifestations in between (Sidransky, 2004). Mutations in
GBA1 have now been established as an important risk factor for the
development of synucleinopathies including Parkinson disease (PD)
(Sidransky et al., 2009), dementia with Lewy bodies (DLB) (Nalls
et al., 2013), and multiple system atrophy (MSA) (Mitsui et al.,
2015). Furthermore, GCase enzyme activity and protein expression
levels are reduced in select brain regions of individuals with PD
without GBA1 mutations (Murphy et al., 2014; Gegg et al., 2012).
Until recently, uncovering GD-associated cellular impairments was
challenging because of the lack of relevant cell models. Primary
dermal fibroblast cultures established from skin biopsies taken from
individuals with GD were the only available cell model to study the
biological implications of GCase deficiency, but these cells do not
store lysosomal substrate. In recent years, intense research on the
link between GBA1 mutations and synucleinopathies, as well as the
development of novel therapeutics, has prompted the development
of novel cell models. The majority of neuronal cell models
commonly used for such studies include wild-type neuroblastoma
cell lines or primary rodent neurons where GCase enzyme activity or
GBA1 expression levels are exogenously modulated by treatment
with the GCase suicide inhibitor conduritol B epoxide (CBE)
(Manning-Bog et al., 2009; Cleeter et al., 2013; Dermentzaki et al.,
2013), transfection with GBA1-specific siRNAs (Mazzulli et al.,Received 4 January 2016; Accepted 12 May 2016
1Section on Molecular Neurogenetics, Medical Genetics Branch, National Human
Genome Research Institute, National Institutes of Health, Bethesda, MD 20892,
USA. 2Postgraduate Program in Cellular and Molecular Biology, Universidade
Federal do Rio Grande do Sul, Porto Alegre, RS 91501-970, Brazil. 3Genomics,
Development, and Disease Section, Genetic Disease Research Branch, National
Human Genome Research Institute, National Institutes of Health, Bethesda, MD
20892, USA. 4Biostrategies LC, State University, AR 72467, USA. 5Laboratory of
Experimental Cancer Research, Department of Radiation Oncology and
Experimental Cancer Research, Ghent University Hospital, Ghent 9000, Belgium.
6Washington University School of Medicine, St. Louis, MO 63110-1093, USA. 7Cell
Biology Section, Neurogenetics Branch, National Institute of Neurological
Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
8Lysosomal Disorders Treatment and Research Program, Clinical Labs, University
of Massachusetts Medical School, Worcester, MA 01655, USA. 9Cytogenetics
Core, National Human Genome Research Institute, National Institutes of Health,
Bethesda, MD 20892, USA.
*Author for correspondence (sidranse@mail.nih.gov)
E.S., 0000-0002-3019-8500
This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution and reproduction in any medium provided that the original work is properly attributed.
769
© 2016. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2016) 9, 769-778 doi:10.1242/dmm.024588
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
2011), or over-expression of plasmids containing mutant GBA1
(Cullen et al., 2011). Although these models have proven useful,
exogenous manipulation of GCase orGBA1 expression often creates
unwanted off-target effects. Primary neuronal cultures from one
mouse model were used to probe mitochondrial function in GD
(Osellame and Duchen, 2013; Osellame et al., 2013). Recently, the
development of induced pluripotent stem cell (iPSC) lines from GD
patients and carriers has gained popularity, providing the
opportunity to develop cell cultures of previously inaccessible
diseased human neurons (Tiscornia et al., 2013; Woodard et al.,
2014; Sun et al., 2015; Schondorf et al., 2014; Awad et al., 2015).
The main disadvantages of both primary rodent neuronal cultures
and iPSC-generated neurons are low cell culture yield and the labor-
intensiveness of establishment and maintenance. We hypothesized
that immortalized GD neurons derived from a GD mouse model
could provide a high-yield, easy-to-maintain alternative for
investigations of the cellular mechanisms involved in GD. Such
immortalized neurons could also have utility for the evaluation of
novel therapeutics and the validation of different reagents and
antibodies.
Immortalization of primary cells is accomplished by exogenous
introduction of immortalizing genes such as the SV40 large T
antigen (SV40-T), which increases lifespan and induces unlimited
proliferation by inactivation of the cell-cycle suppressors pRb,
SEN6 and p53 (Ozer et al., 1996; Tevethia et al., 1998; Manfredi
and Prives, 1994; Ozer, 2000; Jha et al., 1998). Neurons are
terminally differentiated post-mitotic cells, which makes gene
delivery via traditional transfection methods difficult. Lentiviral
expression vectors have the ability to transduce proliferating and
non-proliferating cells, and have been used for infection of primary
rodent neuronal cultures (Lewis et al., 1992; Weinberg et al., 1991;
Zhang et al., 2006; Ding and Kilpatrick, 2013; Eleftheriadou et al.,
2014; Li et al., 2012). In this study, we report the successful SV40-
T-mediated immortalization of mouse cortical neurons derived from
a previously established mouse model deficient in murine
glucocerebrosidase (Tybulewicz et al., 1992).
RESULTS
The EF1α promotor drives expression in cultured mouse
cortical cells
Several independent studies established that promotor
determination for optimal gene expression in a specific cell type
is beneficial (Day et al., 2009; Tsuchiya et al., 2002). Therefore, we
tested a panel of eight different promoters fused to enhanced green
fluorescent protein (eGFP) for their expression capacity in C57BL/6
primary mouse neuronal cultures (Table 1). Brains from 17E
C57BL/6 embryos were harvested and neuronal cultures were
established. Six-day-old primary embryonic cortical neuronal
cultures were transduced with lentivirus containing recombinant
genes encoding mPol2, Grp78, FerH, CAG, CMV13, PGK, EF1α
or TRE-Tight fused to eGFP.We identified the EF1α promotor as an
optimal promoter for primary mouse cortical cells with robust eGFP
expression five days after infection at multiplicity of infection
(MOI) 40 (Fig. 1A). At this point, the infected primary mouse
cortical cell cultures consist of a mixed population of neurons and
glial cells. Our findings were in agreement with previous studies
where EF1α was identified as a suitable promoter for expression in
rat cortical cell cultures and mouse neural precursor cells (Tsuchiya
et al., 2002; Zeng et al., 2003).
EF1α-driven expression of SV40-T immortalizes primary
cortical mouse cells
Exogenous introduction of the immortalizing gene SV40-T is
known to induce proliferation and increase life-span by inactivation
of key cell-cycle suppressors (Ozer et al., 1996; Tevethia et al.,
1998; Manfredi and Prives, 1994; Ozer, 2000; Jha et al., 1998).
Cultures of primary embryonic cortical cells were established
from a previously described mouse model representative of type 2
GD (Tybulewicz et al., 1992). Six-day-old cultures of gba−/− and
gba+/+ cortical cells were infected with EF1α-SV40-T lentivirus at
MOI 40. Five days after infection, SV40-T expressing cells were
selected by treating with puromycin for four weeks. After selection,
the immortalized cortical cell cultures were passaged and expression
of SV40-T was confirmed in protein lysates of immortalized
cultures of each genotype by western blotting (Fig. 1B). Laser
scanning confocal microscopy on cells stained with a nuclear DAPI
stain (Fig. 1D,E) and an anti-SV40T antibody (Fig. 1F,G) revealed
localization of SV40-T in the nucleus (Fig. 1H,I) in immortalized
neurons of both genotypes. To investigate whether SV40-T
expression induces in vivo tumor growth, we performed
intraperitoneal injection with 106 cells of each genotype in Swiss
nu/nu mice and monitored tumor formation. All mice displayed
visible tumors four weeks after injection (Fig. 1C).
Establishment of CD24-positive immortalized neurons
As previously mentioned, cultures established from mouse cortex
contain a mixed cell population consisting of neurons and glial cells.
We performed immuno-cytochemistry on the established SV40-T
immortalized gba+/+ and gba−/− cultures with the neuronal marker
microtubule-associated protein-2 (MAP-2) and the astroglial marker
glial fibrillary acidic protein (GFAP). The immortalized cultures of
each genotype were positive for both microtubule-associated
protein-2 (MAP-2) and glial fibrillary acidic protein (GFAP)
(Fig. 2A,B,E,F). Interestingly, GFAP-positive cells were only
sporadically detected in gba−/− cultures (Fig. 2F). We next selected
cells that were negative for the neural stem and precursor cell marker
CD29 and positive for the differentiated neuron marker CD24
(Pruszak et al., 2007). Immortalized cortical cell cultures of both
genotypes were subjected to positive CD24 selection and negative
CD29 selection using fluorescence-activated cell sorting (FACS)
(Fig. 2C,G). After FACS, the vast majority of cells stained positive
for MAP-2, whereas GFAP-positive cells were absent (Fig. 2D,H).
Multiple studies have shown that SV40-T immortalization of cells
induces aberrant karyotypes (Bloomfield and Duesberg, 2015;
Stoner et al., 1991; Toouli et al., 2002), a phenomenon also
frequently observed in widely used cell lines such as HeLa and
HEK293 (Landry et al., 2013; Stepanenko and Dmitrenko, 2015).
Chromosome analysis on the gba+/+ and gba−/− CD24-positive
immortalized cortical neurons revealed aberrant heterogeneous
Table 1. Promotor panel
Promoter Promoter description Reporter
CMV Human cytomegalovirus immediate early
promoter/enhancer
eGFP
FerH Human ferritin heavy chain promoter, SV40
enhancer
eGFP
mPol2 Murine RNA polymerase II promoter eGFP
Grp78 Hamster glucose-response protein 78
promoter, CMV enhancer
eGFP
CAG Chicken β-actin promoter, CMV enhancer eGFP
PGK Human phosphoglycerate kinase promoter eGFP
EF1α Human elongation factor 1α promoter eGFP
TRE-Tight Modified CMV promoter inducible with
doxycycline
eGFP
770
RESEARCH ARTICLE Disease Models & Mechanisms (2016) 9, 769-778 doi:10.1242/dmm.024588
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
karyotypes, which was expected as the cultures are heterogeneous
and not clonal. Chromosomal abnormalities include numerical
abnormalities (+Y, +5, +14, +16) and morphological abnormalities
like translocation 5;19 (Fig. 3A,B).
gba−/− immortalized neurons have deficient GCase
enzymatic activity and show substrate storage
The previously described neonatal-lethal mouse model of type 2
GD is characterized by severe GCase enzyme deficiency and
accumulation of GlcCer in the brain (Tybulewicz et al., 1992). We
analyzed the CD24-positive immortalized mouse neurons and
found that these characteristics were preserved. gba−/−
immortalized neurons showed a severe deficiency in enzyme
activity (3.40±0.36% relative GCase activity, mean±s.e.m.)
compared with gba+/+ immortalized neurons (93.44±12.26%
relative GCase activity), which was highly significant (P=0.0017)
(Fig. 3C). GCase protein could not be detected in gba−/− lysates
with the previously described GCase-specific inhibody MDW933
Fig. 1. Expression analysis and in vivo tumor formation of SV40-T immortalized mouse cortical cells. (A) EGFP expression in primary C57BL/6 mouse
cortical cell cultures five days after infection with EF1α-eGFP lentivirus at MOI 40. (B)Western blot analysis of protein lysates of gba+/+ (lane 1) and gba−/− (lane 2)
immortalized cortical cells with antibodies against SV40-T and β-actin (protein loading control). SV40-T protein expression was detected in both gba+/+ and gba−/−
immortalized cells. (C) In vivo intraperitoneal tumor formation after injection of 106 cells of gba+/+ and gba−/− immortalized cells in five Swiss nu/nu mice per
genotype. Four weeks after injection, mice injected with gba+/+ cells developed visible solid tumors (left panel) whereas mice injected with gba−/− cells developed
solid bloody tumors (right panel). Immortalized gba+/+ and gba−/−mouse cortical cells were stained for DAPI (D,E), anti-SV40-T (F,G), and the imagemerged with
bright-field for visualization of neuron morphology (H,I). DAPI and SV40-T co-localize in the nucleus (H,I). Scale bar: 20 μm.
Fig. 2. Establishment of CD24-positive gba+/+ and gba−/− neuron cultures. Expression of (A,E) MAP-2 and (B,F) GFAP in SV40-T immortalized gba+/+ and
gba−/− cells before FACS. Both MAP-2 and GFAP are expressed in gba+/+ cultures. GFAP is only sporadically expressed in gba−/− cultures. (C,G) FACS of
SV40-T immortalized gba+/+ and gba−/− cells with antibodies against CD24 and CD29 surface markers. (D,H) Expression of MAP-2 and GFAP in SV40-T
immortalized gba+/+ and gba−/− neuronal cultures after FACS. No GFAP-positive cells are detected. Scale bar: 20 μm.
771
RESEARCH ARTICLE Disease Models & Mechanisms (2016) 9, 769-778 doi:10.1242/dmm.024588
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
(Witte et al., 2010) (Fig. 3D, lane 2). Subsequently, we performed
LC-MS-MS analysis of glycosphingolipids, which revealed
significant GlcCer storage (P=0.0005) in gba−/− immortalized
neurons (1500±118.9 GlcCer/mg protein) compared with gba+/+
immortalized neurons (165.1±6.14 GlcCer/mg protein) (Fig. 3E).
Significant GlcSph storage (P<0.0001) was observed in gba−/−
immortalized neurons (485.7±21.24 GlcSph/mg protein) compared
with gba+/+ immortalized neurons (0.071±0.02 GlcSph/mg protein)
(Fig. 3F). Next, we analyzed expression of alpha-synuclein (α-syn),
which is a small protein (14 kDa) with abundant expression in
neurons. Aggregation of α-syn results in the formation of insoluble
oligomeric and fibrillar inclusions, a prominent pathological feature
in the brain of individuals with synucleinopathies (Fearnley and
Lees, 1991; Puschmann et al., 2012; Puschmann, 2013). High α-syn
protein expression has been reported in cultured primary mouse
neurons, including gba-deficient mouse neurons (Osellame et al.,
2013). Western blot analysis with two different antibodies against
α-syn did not show any monomeric α-syn protein expression in
gba+/+ and gba−/− immortalized mouse neurons (data not shown).
Although it has been shown that treatment with retinoic acid, an
agent that induces neuronal differentiation (Manning-Bog et al.,
2009), and valproic acid, a histone deacetylase inhibitor, can
increase α-syn protein and mRNA levels in primary cultures of rat
cerebellar granule cells (Leng and Chuang, 2006), treating
immortalized gba+/+ and gba−/− cortical neuron cultures with
1 mM valproic acid for 4 days or 10 μM retinoic acid for 6 days did
not result in endogenous α-syn protein expression (data not shown).
gba−/− immortalized neurons have enlarged lysosomes
Gaucher cells, engorged macrophages with lysosomal GlcCer
accumulation, are primarily found in the spleen, liver and bone
marrow of individuals with GD (Sidransky, 2012). These typical
enlarged, lipid-laden lysosomes were previously identified in the
liver and bone marrow of gba−/−mice (Tybulewicz et al., 1992). We
investigated whether the CD24-positive gba−/− neurons, which
show GlcCer and GlcSph substrate storage (Fig. 3E,F), have
enlarged lysosomes by estimating the lysosomal volume per cell in
gba+/+ and gba−/− neurons using LysoTracker®, which specifically
stains acidic endosomal compartments. Using an established FACS
analysis method to calculate the fold-change in LysoTracker® as the
Fig. 3. Karyotyping, GCase enzyme activity, protein expression and substrate levels in immortalized gba+/+ and gba−/− neurons. (A,B) Karyotyping of
immortalized CD24-positive gba neurons. Two examples each of heterogeneous karyotypes observed for immortalized gba+/+ and gba−/− mouse neurons.
(C) GCase enzyme activity in SV40-T immortalized gba+/+ and gba−/− mouse neurons. Relative percentage GCase enzyme activity of gba−/− (3.40±0.36%)
immortalized neurons is significantly lower compared with gba+/+ immortalized neurons (93.44±12.26%) (P=0.0017). Each enzyme assay was performed three
independent times (n=3) in triplicates. The data are represented as relative mean values±s.e.m. (D) 15 µg of neuronal protein lysatewas incubated with 100 nM of
the GCase-specific MDW933 fluorescent inhibody. GCase protein expression is absent in gba−/− immortalized neurons (lane 2). Recombinant imiglucerase
was loaded as a positive control (lane 3). (E) Gba−/− immortalized neurons show significantly increased GlcCer storage compared with gba+/+ immortalized
neurons (1500±118.9 vs 165.1±6.14 GlcCer/mg protein; P=0.0005). (F) Gba−/− immortalized neurons show significantly increased GlcSph storage compared
with gba+/+ immortalized neurons (485.7±21.24 vs 0.071±0.02 GlcSph/mg protein; P<0.0001). Each substrate storage assay was done four independent times
(n=4). The data are represented as mean values±s.e.m.
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ratio of the geometric means of LysoTracker® in stained and
unstained samples (Rodriguez-Gil et al., 2013), we detected a
significant increase (P=0.0003) in intensity of LysoTracker®
staining of gba−/− neurons (fold-change 17.7±0.83) compared
with gba+/+ (fold-change 7.13±0.23) (Fig. 4A). This was confirmed
with a 96-well high-throughput imaging assay (Acosta et al., 2015)
where enlarged lysosomes had increased LysoTracker® signal
intensity, reflecting the size and number of acidic endosomes. After
segmentation, the number of LysoTracker® objects or region of
interest (ROI) and total pixels per image were quantified and
divided by the number of cells in the image. Lysosomal volume in
gba−/− cells (80.22±1.79), measured as total LysoTracker®
pixels per cell, was almost four times greater than gba+/+ cells
(22.12±1.85) (Fig. 4B). The number of ROIs acquired per cell was
also significantly higher in gba−/− (6.79±0.11) compared with
gba+/+ (2.36±0.13) (Fig. 4C).
gba−/− neurons show an impaired ATP-dependent Ca2+
response
Previous studies have shown that rodent neuronal cell models and
brain samples from individuals with GD showed increased Ca2+
release from intracellular Ca2+ stores such as the endoplasmic
reticulum (ER) into the cytosol (Korkotian et al., 1999; Pelled et al.,
2000, 2005; Lloyd-Evans et al., 2003a,b). Cytosolic Ca2+ can also
be modulated by influx of Ca2+ from the extracellular environment
into the cytosol via ATP-selective purinergic receptors (P2X
receptors), which are expressed on the plasma membrane of glial
cells and neurons (Saez-Orellana et al., 2015). We measured ATP-
dependent Ca2+ influx with the intracellular Ca2+ marker Fluo-4
AM (Fig. 4D). Immediately after treatment with 3 µM, 1 µM,
0.3 µM or 0.1 µM of ATP, we observed a significant dose-
dependent elevation of Ca2+ influx in gba+/+ (black dots)
compared with gba−/− neurons (white dots) (P=0.0036), which
suggest that treatment with ATP failed to induce Ca2+ influx in
gba−/− neurons (Fig. 4D). The Ca2+ influx data was normalized to
the number of cells seeded in each well of the 96-well plate with the
CellTag 700 assay.
DISCUSSION
The establishment of high-yield and easy-to-manipulate
immortalized gba−/− neuronal cells from a previously described
gba-deficient mouse model can serve as a valuable tool to test newly
discovered cellular mechanisms or therapeutics. This is particularly
useful before moving to primary neurons or iPSC-derived neurons,
which have a low cell culture yield, are costly, and are labor-
intensive to establish and maintain. Most other available neuronal
cell models rely on the GCase suicide inhibitor CBE, gba1 gene
silencing, or exogenous introduction of GBA1 mutants to modulate
GCase (Manning-Bog et al., 2009; Cleeter et al., 2013; Dermentzaki
et al., 2013; Mazzulli et al., 2011; Cullen et al., 2011).
Primary neurons are post-mitotic cells that are terminally
differentiated. However, upon introduction of SV40-T, primary
cells are forced into proliferation resulting in increases in life-span
(Ozer et al., 1996; Tevethia et al., 1998; Manfredi and Prives,
1994; Ozer, 2000; Jha et al., 1998). After SV40-T-mediated
immortalization, we obtained actively dividing cortical cells that
retained the neuronal marker MAP-2 and glial marker GFAP. FACS
on cortical cell cultures allowed us to isolate CD24-positive
neurons, which were exclusively positive for MAP-2 and negative
GFAP. Cellular defects observed in the mouse model such as the
absence of GCase protein expression and enzyme activity as well as
elevated levels of GlcCer and GlcSph substrate (Tybulewicz et al.,
Fig. 4. Quantitative analysis of
lysosomes and ATP-dependent Ca2+
influx in immortalized gba +/+ and gba−/−
neurons. (A) FACS analysis of
LysoTracker stained gba−/− neurons and
gba+/+ (fold-change 17.7±0.83 vs 7.13±
0.23). Data from three independent
experiments (n=3) showed significantly
increased LysoTracker staining in gba−/−
neurons (P=0.0003). (B) Total
LysoTracker® pixels per cell was
significantly higher in gba−/− cells
compared with gba+/+ cells (80.22±1.79 vs
22.12±1.85; P=0.0005). (C) The number
of ROIs acquired per cell was significantly
higher in gba−/− cells compared with
gba+/+ cells (6.79±0.11 vs 2.36±0.13;
P=0.0005). (D) After treatment of cells with
different concentrations of ATP (3 µM,
1 µM, 0.3 µM, 0.1 µM), Ca2+ influx in
gba+/+ (black dots) was significantly higher
(P=0.0036) compared with gba−/− (white
dots). Experimental data was normalized
to numbers of cells with the CellTag 700
assay. Each experiment included
quadruplicate samples and was repeated
two times (n=2). The data are represented
as mean values±s.e.m.
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1992) were all maintained in our established SV40-T immortalized
gba−/− neurons. Previously, lysosomes in fibroblasts of the rare
recessive lysosomal storage disorder Niemann–Pick C disease
(NPC1; MIM #257220) were analyzed with FACS using
LysoTracker® staining, a fluorophore selective for acidic cellular
organelles. The LysoTracker® signal was significantly elevated in
NPC1 patient fibroblasts and these lysosomal alterations seemed to
directly correlate to the time of onset of neurological disease
symptoms (Rodriguez-Gil et al., 2013). Using the same method, we
found a significant increase in LysoTracker® intensity in gba−/−
immortalized neurons; this was confirmed by an established high
content fluorescence microscopy assay (Acosta et al., 2015). This
finding indicates that substrate storage in gba−/− neurons could lead
to enlarged lysosomes.
Mutations in GBA1 are an important risk factor for the
development of several synucleinopathies including PD, DLB and
MSA (Mitsui et al., 2015; Nalls et al., 2013; Sidransky et al., 2009).
The main pathological feature is the presence of α-syn aggregates
and inclusions (Fearnley and Lees, 1991; Puschmann et al., 2012;
Puschmann, 2013). Recent in vitro and in vivo studies favor a
reciprocal relationship between GCase and α-syn, where diminished
GCase enzyme activity or protein expression increases
accumulation of α-syn or where increased α-syn protein levels
result in reduced GCase activity and protein expression (Gegg et al.,
2012; Murphy and Halliday, 2014; Chiasserini et al., 2015;
Mazzulli et al., 2011; Sardi et al., 2015). Additional evidence in
favor of this model came from cultures of primary neurons from the
midbrain of an inducible neuronopathic GD type 2 mouse model
(gba−/−) with significant accumulation of endogenous α-syn
(Osellame et al., 2013), suggesting that absent GCase favors
α-syn accumulation. We analyzed expression of monomeric α-syn
in our SV40-T immortalized gba−/− and gba+/+ neurons but failed
to detect α-syn protein, which is similar to what has previously been
described in actively dividing neuroblastoma cell lines such as SH-
SY5Y. In contrast to other published rodent and human neuronal
lines, we did not observe enhanced α-syn protein levels when
immortalized neurons were treated with retinoic acid or the histone
deacetylase inhibitor valproic acid (Manning-Bog et al., 2009; Leng
and Chuang, 2006). Because the immortalized CD-24-positive
mouse neurons do not express endogenous α-syn, caution has to be
taken when using these cells as a tool to investigate the relationship
between GCase and α-syn. To address this, introduction of
exogenous α-syn by plasmid transfection or lentiviral infection
could be performed, which is a strategy used for actively dividing
neuroblastoma cells that lack endogenous α-syn such as SH-SY5Y
(McNeill et al., 2014; Dermentzaki et al., 2013).
Previous studies showed increased Ca2+ release into the cytosol
from intracellular Ca2+ stores in cells and tissues with GlcCer and
GlcSph storage. Current literature proposes that elevated GlcCer
levels contribute to neuronal cell death via increased ryanodine
receptor-dependent Ca2+ release, whereas GlcSph storage enhanced
Ca2+ release via the inositol (1,4,5)-trisphosphate receptor (InsP3R)
and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA)
(Korkotian et al., 1999; Pelled et al., 2000, 2005; Lloyd-Evans et al.,
2003a,b). Cytosolic Ca2+ concentration also depends on the influx
of Ca2+ from the extracellular environment, which is dependent
upon ATP-selective P2X receptors expressed on the plasma
membrane of glial cells and neurons (Saez-Orellana et al., 2015;
Volonte et al., 2003). ATP-dependent P2X receptor-mediated Ca2+
influx in neurons is described to be involved in the modulation of
neurotransmitter release, synaptic plasticity (Saez-Orellana et al.,
2015), and even lysosomal dysfunction and α-syn aggregation (Gan
et al., 2015). Further research is needed to uncover the exact role of
the different P2X receptors in the impaired ATP-dependent Ca2+
influx in gba−/− neurons and the associated implications on
neurological function.
Multiple studies have shown that SV40-T-mediated
immortalization of primary cells induces aberrant karyotypes
(Bloomfield and Duesberg, 2015; Stoner et al., 1991; Toouli et al.,
2002), which is also frequently observed in widely used cell lines
such as HeLa and HEK293 (Landry et al., 2013; Stepanenko
and Dmitrenko, 2015). Chromosomal analysis of the immortalized
gba+/+ and gba−/− CD24-positive neuronal cultures revealed
heterogeneous aberrant karyotypes, which was expected as the
cultures are not clonal. We are confident that the observed
phenotypes are related to absence of gba1 and not random
integration location. Recently, Gramlich and co-workers used this
immortalized gba−/− cell model as an in vitro model for the
evaluation of neuronal uptake and substrate turnover of newly
developed recombinant GCase proteins. Uptake of GCase proteins
intogba−/− neurons showed a significant reduction ofGlcSph storage
(Gramlich et al., 2016).Wewere aware that phenotype drifting might
happen; however, confirmation of experimental reproducibility on
different cell passage numbers revealed little variation.
In summary, we describe the first successful SV40-T-mediated
immortalization of mouse cortical neurons derived from a
previously established gba-deficient mouse model (Tybulewicz
et al., 1992). The immortalized gba−/− neurons express neuronal
markers and exhibit a gba-deficient phenotype characterized by
GCase enzyme deficiency, absent GCase protein expression, and
significant accumulation of GlcCer and GlcSph. This original
neuronal cell line constitutes a relevant, high-yield, and easy-to-
manipulate in vitro tool for not only assessing the molecular and
cellular defects associated with GD, but also for developing and
evaluating novel therapeutic strategies (Gramlich et al., 2016).
MATERIALS AND METHODS
Culturing of primary mouse neurons
Animal studies were in accordance with protocol G-05-4, which was
approved by NHGRI Animal Care and Use Committee (National Institutes
of Health, Bethesda, MD, USA). Brains from gba-deficient or C57BL/6
mouse embryos at day 17 (17E) were harvested and placed in cold dissecting
media [10 ml L15 media, 0.15 ml HEPES buffer, and 0.15 ml pen/strep
(Life Technologies, Grand Island, NY, USA)]. The meninges was removed,
cortices were isolated, minced and incubated for 45 min at 37°C in papain
solution with DNaseI (Worthington Biochemical Corporation, Lakewood,
NJ, USA). Minced cortices were gently triturated (10-15 times) followed by
centrifugation at 164 g for 5 min at room temperature (RT). The supernatant
was removed and cell pellet was resuspended in 500 µl papain inhibitor
(Worthington Biochemical Corporation) with DNaseI. After 10 min, stop
solution was aspirated and 10 ml of a 10/10 solution HBSS (Life
Technologies), 0.1 g trypsin inhibitor (Sigma Aldrich, St. Louis, MO,
USA), 0.1 g BSA fraction V (Sigma Aldrich) was added to the settled cells.
The cells were spun down at 105 g for 10 min. After removing the
supernatant, cell pellets were resuspended in 2 ml neurobasal growth media
[500 ml neurobasal media, 1:50 (v/v) B27, 1:200 (v/v) glutamine, and
25 mM HEPES (Life Technologies)]. 500 µl of cell suspension with 2.5 ml
of neurobasal growth media was added to each well of a 6-well plate pre-
coated with poly-L-lysine (Sigma Aldrich). 50% of the neurobasal growth
media was changed every 3 days.
Chemicals and antibodies
Conduritol B epoxide (CBE) (Sigma Aldrich), an irreversible inhibitor of
glucocerebrosidase, was dissolved in DMSO to a stock solution of 100 μM.
Valproic acid (Sigma Aldrich), a histone deacetylase inhibitor, was
dissolved in ethanol to a stock solution of 200 mM. The following
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antibodies were used for western blotting: anti-SV40T mouse monoclonal
(Santa Cruz Biotechnology Inc., CA, USA, sc-148, 1:2000), anti-α
synuclein rabbit polyclonal (Santa Cruz Biotechnology Inc., sc-7011-R,
1:1000), anti-α synuclein polyclonal (EMDMillipore, Billerica, MA, USA,
AB5038, 1:1000), anti-beta Actin conjugated to HRP (Abcam, Cambridge,
MA, USA, ab20272, 1:5000), andMAP-2 rabbit polyclonal (Cell Signaling,
Danvers, MA, USA, 8707S, 1:1000). The following antibodies were used
for immunocytochemistry: anti-SV40T mouse monoclonal (Santa Cruz
Biotechnology Inc., sc-148, 1:100), anti-GFAP rabbit polyclonal (Abcam,
ab16997, 1:100), anti-MAP2 chicken polyclonal (Abcam, ab92434, 1:100).
Lentiviral vector production and transfection
Lentiviral plasmid DNA was co-transfected with ViraPower Lentiviral
packaging plasmids (Life Technologies) into HEK293T cells to generate
VSV-g pseudotyped lentivirus particles. The cells received fresh DMEM
media (Life Technologies) 24 h post-transfection and the culture
supernatant was harvested 48 h post-transfection. The crude lentivirus
stock was filtered, centrifuged and concentrated using Amicon Ultra-15
columns (EMDMillipore). Virus titer was determined with the Global Ultra
Rapid Lentiviral Titer kit (System Biosciences, Mountain View, CA, USA)
according to the manufacturer’s guidelines. Lentiviral particles were
infected at multiplicity of infection (MOI) 40 with the TransDux reagent
according to the manufacturer’s guidelines (System Biosciences).
Promotor testing and immortalization of primary mouse neurons
Packed lentiviral particles, containing enhanced green fluorescent protein
(eGFP) driven by distinct promoters (mPol2, Grp78, FerH, CAG, CMV13,
PGK, EF1α, TRE-Tight), were ordered from Leidos Biomedical Research
Inc. (Frederick, MD, USA). 6-day-old primary cortical neuron cultures from
C57BL/6 mice were infected at MOI 10, 20 and 40 with the TransDux
reagent. eGFP expression was evaluated after 5 days of infection with a
fluorescence microscope (Zeiss, San Diego, CA, USA). Packed lentiviral
particles containing EF1α-SV40T were ordered from Leidos Biomedical
Research Inc and 6-day-old primary cortical neuron cultures from gba−/−
and gba+/+ mice were infected at MOI 40 with TransDux reagent
(System Biosciences). After 4 days of infection, the cultures were treated
with 1 µg/ml of puromycin (Sigma Aldrich) for 4 weeks; the media was
changed every 3 days.
In vivo tumor formation
Animal studies were in accordance with a protocol approved by the Local
Ethics Committee of Ghent University Hospital (Ghent, Belgium). At the
age of 5 weeks, female Swiss nu/nu mice (five mice per genotype; Charles
River Laboratories, Brussels, Belgium) were injected intraperitoneally with
106 cells resuspended in 100 μl matrigel. Tumor growth was assessed after
4 weeks of injection.
Spectral karyotyping
Metaphase slides were prepared after mitotic arrest with 2-4 h Colcemid
(0.015 μg/ml; Thermo Fisher Scientific), 20 min hypotonic treatment
(0.075 mol/l KCl, 37°C), and fixation with methanol–acetic acid (3:1). For
spectral karyotyping we used commercial SKY probe (Applied Spectral
Imaging Inc., Carlsbad, CA, USA) allowing the visualization of the
individually colored chromosomes. This technique is used to identify
structural and numerical chromosome aberrations in mouse cell lines
(Schrock et al., 1996).
Immunocytochemistry and laser scanning confocal microscopy
Cells were grown for 48 h on Lab-Tek chamber slides (Thermo Scientific,
Waltham, MA, USA). Cells were fixed in 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA, USA), blocked in 1× PBS (Life
Technologies) containing 0.1% saponin (Sigma Aldrich), 100 μM glycine
(Sigma Aldrich), and 2% donkey serum (Jackson Immunoresearch
Laboratories Inc, West Grove, PA, USA) followed by a 4°C overnight
incubation with primary antibodies. Cells were washed with 1× PBS and
incubated with the following secondary antibodies (all from Life
Technologies): anti-mouse Alexa Fluor 488 (A-11001; 1:300), anti-
chicken Alexa Fluor 488 (A-11039; 1:300), anti-rabbit Alexa Fluor 555
(A-21428; 1:300), for 1 h at RT, washed again, and mounted with Prolong
Gold antifade reagent with or without DAPI (Life Technologies). Cells were
imaged with a Zeiss 510 META confocal laser-scanning microscope (Carl
Zeiss Microscopy, Munich, Germany) using a 488 argon, a 543 HeNe, and a
diode laser. Images were acquired using a Plan NeoFluar 40×/1.3 oil DIC
objective or a Plan Apochromat 63×/1.4 oil DIC objective. Bright-field
images were obtained for visualization of neuron morphology.
Fluorescence-activated cell sorting (FACS)
Neurons and glial cells of immortalized gba−/− and gba+/+ neuronal cultures
were separated by FACS. Cells of each genotype were labeled with FITC
hamster anti-rat CD29 and PE rat anti-mouse CD24 (BD Biosciences, San
Jose, CA, USA). Single-stained and unstained cells were used as a control.
Cells were sorted using a BD FACSAriaII cytometer (BD Biosciences).
Results were analyzed with FACSDiva software version 6.1.3 (BD
Biosciences).
Western blotting
The amount of protein for each sample was determined by DC™ protein
assay (Bio-Rad Laboratories, Hercules, CA, USA). An equal amount of
protein for each sample was loaded onto a 4-20% Mini-PROTEAN®
TGX™ gel (Bio-Rad Laboratories). After blotting with the Trans-Blot
Turbo transfer system (Bio-Rad Laboratories), PVDF membranes (Bio-Rad
Laboratories) were blocked for 1 h at RT in blocking solution [1× PBS,
0.5% (v/w) milk, 0.1% Tween (Sigma Aldrich)]. PVDF membranes were
probed overnight with primary antibodies in blocking solution at 4°C.
PVDF membranes were washed 3×5 min at RTwith blocking solution. This
was followed by incubation with HRP-coupled secondary anti-mouse or
anti-rabbit antibodies (Amersham Biosciences, Piscataway, NJ, USA,
NA931 and NA934, respectively, 1:4000). PVDF membranes were washed
3×5 min with blocking solution followed by 3×5 min with 1× PBS plus
0.1% Tween. The antigen-antibody complexes were detected with an
Enhanced Chemiluminescence (ECL) kit (Amersham Biosciences).
Quantification of GCase protein levels
Florescent activity-based probes specific for GCase (MDW933) were
synthesized at the Imaging Probe Development Center (National Heart Lung
and Blood Institute, Bethesda, MD, USA) as previously described (Witte
et al., 2010). Total protein concentration of each sample was measured using
a Bradford assay according to the manufacturer’s guidelines (Bio-Rad
Laboratories). Cell homogenate was incubated with 1 μM of green
fluorescent MDW933 probe in citrate phosphate buffer (pH 5.4) at 37°C
for 90 min. Samples were analyzed on a 4-20% Mini-PROTEAN® TGX™
gel (Bio-Rad Laboratories) using 1.2 μM imiglucerase (Genzyme,
Cambridge, MA, USA) with 1 μM MDW933 probe as a control. A
Typhoon Variable Mode Imager (Amersham Biosciences, Piscataway, NJ,
USA), set to excitation wavelength (λex)=488 nm and emission wavelength
(λem)=520 nm, was used to measure the fluorescent signal in the gel.
GCase enzyme activity assay
Cell lysates were prepared in citrate-phosphate extraction buffer [150 mM
citrate-phosphate buffer pH 5.4, 0.25% Triton X-100, protease inhibitor
mix (Roche Diagnostics, Indianapolis, IN, USA)] and sonicated for 20 s
at 50% amplitude using a mechanical tissue homogenizer (Omni
International, Kennesaw, GA, USA). Cell homogenates were then
centrifuged at 10,000 g for 15 min at 4°C. GCase enzyme activity was
measured in an assay buffer composed of citrate-phosphate buffer (pH 5.4)
with 10 mM 4-methylumbelliferyl-β-D-glucopyranoside (Sigma Aldrich).
Cell homogenate (5 μl) was added to each individual well of a black 384-
well plate (VWR International, Bridgeport, NJ, USA) and each sample was
read in triplicate. To correct for cytosolic gba2 activity, 5 μl of a 100 μM
CBE solution (Sigma Aldrich) was added in triplicate and assay buffer was
pipetted to each well to bring the total assay volume to 30 μl. The plate was
briefly centrifuged and then incubated at 37°C for 1 h at 600 rpm. The
reaction mixtures were quenched by the addition of 30 μl of stop solution
(1 M glycine, pH 12.5) and fluorescence was measured using a FlexStation
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3 Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA,
USA), at λex=520 nm and λem=440 nm. Enzyme activity was normalized
based on total protein amount. Data were analyzed by a Student’s two-tailed
t-test and are represented as mean±s.e.m.
FACS analysis for lysosomal size
gba−/− and gba+/+ neurons were plated in 60 mm tissue culture dishes
(VWR International) and grown to 80% confluency. The cells were given
fresh neurobasal growth media 24 h before analysis. On the day of analysis,
cells were incubated with neurobasal media supplemented with 1 μM
Lysotracker Red DND-99 (Thermo Fisher Scientific) for 1 h at 37°C. FACS
analysis was performed on a FACSCalibur (BD Biosciences, Franklin
Lakes, NJ, USA) according to a previously described protocol (Rodriguez-
Gil et al., 2013). Biological duplicates were analyzed in three independent
experiments (n=3). Fold-change was calculated as the ratio of the geometric
means of Lysotracker Red stained and unstained samples. Data were
analyzed by a Student’s two-tailed t-test and represented as mean±s.e.m.
High-throughput imaging for lysosomal size
A recently described protocol was optimized for high-throughput imaging on
SV40 immortalized gba−/− and gba+/+ neurons (Acosta et al., 2015). The cell
lines were plated in a black clear bottom 96-well plate in neurobasal media.
Sixteen wells per cell line were plated. After 72 h, cells were treated with
1 µM Lysotracker Red (Life Technologies) for 20 min and washed with 1×
PBS. Cells were fixed with 4% paraformaldehyde for 5 min followed by 3×
washes with PBS. Cells were counterstained with 300 nM DAPI (Life
Technologies). The BD Pathway® 855 High Content Bioimager (BD
Biosciences, Franklin Lakes, NJ) was used to acquire images in each well
under identical settings for exposure, dynamic range, and laser autofocus.
Images for each well were taken using a 2×2 montage with the 20× objective
yielding an average of 400 cells per image (∼6400 cells per treatment). For
each well, fluorescent signal (excitation/emission) was acquired at
λex=560 nm and λem=645 nm for the red signal and λex=380 nm and
λem=435 nm for the blue signal. Image segmentation was performed using
Attovision® software (BD Biosciences). Cell count was obtained using
polygon segmentation for the nucleus DAPI signal. LysoTracker® regions of
interest (ROI) were obtained by polygon segmentation of one of each
compartment detected in the red signal. Segmentation data was analyzed
using BD Data Explorer® software (BD Biosciences). An average of
LysoTracker® pixels per cell was calculated for each image. Averages of the
sixteen images (n=16) were used to estimate the value of each treatment.
Data were analyzed by a Student’s two-tailed t-test and represented as
mean±s.e.m.
Lipidomics
Glycosphingolipids (glucosyl- and galactosyl-sphingosines, glucosyl- and
galactosyl-ceramides)were extractedwithmethanol frommouse homogenized
immortalized neurons containing N,N-dimethylgalactosylsphingosine and
galactosylceramide (d18:1 8:0) as internal standards. Glycosphingolipid
analysis was initially carried out for quantification of glycosylsphingosines
and glucosylceramides using a Varian reverse phase C-18metasil column that
was connected to an API 4000 LC-MS-MS system (Applied Biosystems).
Later isomer separation of glycosphingolipids was performed using a Supelco
HILIC column for determination of the isomer composition. Positive ion
electrospray method using MRM was used for both analyses. Data were
normalized to protein content in the samples. Datawas analyzed bya Student’s
two-tailed t-test and represented as mean±s.e.m.
Calcium assay
On day one, SV40-T immortalized neurons were seeded at 70% confluency
in a black flat clear bottom 96-well plate (Corning Inc, Kennebunk, ME).
On day 3, neurobasal media was removed from the cells and assay buffer,
which consists of physiological salt solution (PSS) buffer (126 mM NaCl,
5 mM KCl, 1.2 mM MgCl2, 10 nM HEPES, 10 nM glucose, 1 nM CaCl2)
+0.2 mM sulfinpyrazone+0.1 mM CaCl2+12 µl pluronic F-127 (Life
Technologies)+60 µg fluo-4 AM (Life Technologies), was added and
incubated for 1 h at 37°C and 10%CO2. Assay buffer was removed and cells
were washed once with 1× PBS followed by incubation with PSS buffer+
0.2 mM sulfinpyrazone+0.1 mM CaCl2 for 10 min at 37°C and 10% CO2.
The 96-well plate was inserted into the Flexstation 3 plate reader
(Molecular Devices, Sunnyvale, CA) and the cells were treated with
10 µM, 3 µM, 1 µM, 0.3 µM and 0.1 µM of ATP dissolved in PSS buffer.
PSS buffer without ATP was included as a negative control. The Flex mode
setting was used with λex=494 nm and λem=516 nm. ATP-dependent Ca
2+
response was followed for 120 s over 10 s intervals with six readings per
well. The experiment included quadruplicate samples per plate and was
repeated two independent times. Dose-dependent curves were fitted and
EC50 was calculated.
CellTag 700 assay
After data acquisition on the Flexstation-3 plate reader, the cells in the black
96-well plate were fixed in 4% paraformaldehyde for 1 h at RT. This was
followed by permeabilization with 0.1% Triton-X (Sigma Aldrich) for
10 min at RT. The cells were washed with 1× PBS followed by incubation
with CellTag 700 (LI-COR Biosciences, Lincoln, NE, USA) (1:3000) for
1 h at RT. After washing twice with 1× PBS, the plate was dried and imaged
on the LI-COR imaging station (LI-COR Biosciences).
Statistical analysis
Data obtained from GCase enzyme activity, substrate storage, and
lysosomes were analyzed by a Student’s two-tailed t-test with GraphPad
Prism® software version 6.0 (GraphPad, San Diego, CA, USA) and data are
represented as mean±s.e.m. For ATP-dependent Ca2+ response, dose curves
were fitted and EC50 was calculated with the GraphPad Prism®
(version 6.0).
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